Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03857503 · ClinicalTrials.gov registry record
Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)
A clinical trial, sponsored by Volcano Corporation.
- Completed
- Registry status
- 441
- Enrollment target
NCT03857503: Completed study, sponsored by Volcano Corporation.
NCT03857503 is a clinical trial that has completed, run by Volcano Corporation. The registered enrollment target is 441 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03857503 has completed, sponsored by Volcano Corporation.
- COMPLETED
- Registry status
- 441 participants
- Enrollment target
Study Summary
The Philips Angio-iFR medical software device is intended to provide information on the functional significance of a coronary artery lesion to provide guidance on diagnostic decisions similar to that obtained through invasive measures of iFR and FFR. The software application uses the vessel geometry obtained from a coronary angiographic image together with a lumped parameter physiological model to provide the associated iFR and FFR estimates.
Primary Outcome
Diagnostic accuracy of the image-derived iFR and FFR estimate for a given lesion compared to the corresponding invasive iFR and FFR values.
Interventions
- DIAGNOSTIC_TEST iFR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2021-03-12 |
What the finished NCT03857503 record still lists
NCT03857503 is an observational study that tracks outcomes without assigning an intervention. The registered 441 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which iFR is the first listed.
NCT03857503 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03857503 about?
NCT03857503 is a clinical study titled "Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)". The Philips Angio-iFR medical software device is intended to provide information on the functional significance of a coronary artery lesion to provide guidance on diagnostic decisions similar to that obtained through invasive measures of iFR and FFR. The software application uses the vessel geometry...
What is the current status of trial NCT03857503?
This trial is currently completed. The enrollment target is 441 participants. The study started on 2019-08-01. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT03857503?
The interventions under investigation include: iFR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03857503?
This trial is sponsored by Volcano Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02679144 · 441 participants · Phase 2
Neuroblastoma Maintenance Therapy Trial
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT04657068 · 442 participants · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI